Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Among individuals with schizophrenia, the risk for natural-cause mortality was increased in those with reduced cognitive functioning.

Cobenfy also contains trospium, which blocks some of the side effects. The most common are nausea, vomiting and indigestion.

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

Unsupervised use of hallucinogens like LSD is high, posing significant risks. However, LSD is being clinically tested for treating anxiety and so far seems effective.

The mother of a slain paramedic sobbed as she told his killer “the last breath I take on this earth” would be infected with ...

Vincent Paulette got into drugs when he was 8 years old. When the college-educated 25-year-old found himself navigating ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

Steven Tougher’s wife sobbed as she recounted giving birth to the couple’s child in the weeks after his stabbing death ...

Most kids with attention issues won't go on to develop serious psychiatric conditions like psychosis or schizophrenia.

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

Relative to placebo, lumateperone significantly improved MADRS, CGI-S, and QIDS-SR-16 scores by day 43 among patients with MDD.